A compound of competence
OUR FOCUS is on PN6047, a novel potent and selective, biased delta-opioid receptor agonist, which is predicted to reduce common symptoms of chronic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.
In various pre-clinical studies, PN6047 has shown high selectivity and potency, and very convincing efficacy in reducing neuropathic pain without any indications of the unwanted side effects of traditional opioids such as respiratory depression and abuse potential.
PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favourable dosing in humans. Its metabolic profile also indicates possibilities for developing combination therapies.
PN6047 has fully drug-able properties and characteristics supporting asolid dosage form.
